Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neos Therapeutics, Inc.NEOS · Entity 141061 | Chief Executive Officer | March 01, 2018 | March 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neos Therapeutics, Inc.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,748 |
Reported balance
After 2018-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 25,000 · Balance 160,748 F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2028-03-01 | Direct | 75,000 |
Reported balance
After 2018-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-01 · Grant · Acquired 75,000 · Balance 75,000 F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019.
F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altimmune, Inc.
Report date January 30, 2026 · Filed February 02, 2026
Section 16 reporting ended · disclosed 2026-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 424,519 |
Ending reported balance
After 2026-01-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-30 · Exercise / conversion · Acquired 26,775 · Balance 429,225 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-01-30 · Tax withholding · Disposed 11,632 · Balance 417,593 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Row 3 · 2026-01-31 · Grant · Acquired 6,926 · Balance 424,519 F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026 F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,775 |
Reported balance
After 2026-01-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-30 · Exercise / conversion · Disposed 26,775 · Balance 26,775 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025
F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2026 Filed Feb 2, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 6,926 | $3.07 | $21,262.82 |
DisclosureSEC source: 0001515813-26-000006 · form4-02022026_040201.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,519 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026 F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000006 · form4-02022026_040201.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,775 Underlying: Common Stock, par value $0.0001 · 26,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 11,632 | $5.60 | $65,139.20 |
DisclosureSEC source: 0001515813-26-000006 · form4-02022026_040201.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,593 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000006 · form4-02022026_040201.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 41,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000004 · form4-01292026_040103.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,600 Underlying: Common Stock, par value $0.0001 · 41,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 17,898 | $6.18 | $110,609.64 |
DisclosureSEC source: 0001515813-26-000004 · form4-01292026_040103.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,450 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 41,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000004 · form4-01292026_040103.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 42,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000002 · form4-01272026_070101.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,100 Underlying: Common Stock, par value $0.0001 · 42,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 17,984 | $5.50 | $98,912.00 |
DisclosureSEC source: 0001515813-26-000002 · form4-01272026_070101.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,148 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 42,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001515813-26-000002 · form4-01272026_070101.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · derivative · entry 10 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,950 Underlying: Common Stock, par value $0.0001 · 18,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 8,282 | $6.64 | $54,992.48 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 7 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,082 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 6 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · derivative · entry 9 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 16,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F6 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 7,231 | $6.64 | $48,013.84 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,414 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 4,105 | $5.18 | $21,263.90 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,100 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2024. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · derivative · entry 8 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,550 Underlying: Common Stock, par value $0.0001 · 26,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 11,701 | $7.00 | $81,907.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,995 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008773 · tm255357-4_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:04 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 164,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006837 · tm254755-1_4seq1.xml · derivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,800 Underlying: Common Stock, par value $0.0001 · 164,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:04 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 477,500 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006837 · tm254755-1_4seq1.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,500 Underlying: Common Stock, par value $0.0001 · 477,500 shares Expires 2035-01-27 F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and released on January 27, 2026 and the remaining 75% of the shares underlying the option become vested and released in substantially equal monthly installments over the 36 months following January 27, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:04 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 42,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006837 · tm254755-1_4seq1.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,150 Underlying: Common Stock, par value $0.0001 · 42,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:04 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 18,157 | $6.98 | $126,735.86 |
DisclosureSEC source: 0001104659-25-006837 · tm254755-1_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,921 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:04 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 42,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006837 · tm254755-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · derivative · entry 6 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,900 Underlying: Common Stock, par value $0.0001 · 18,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 8,376 | $9.32 | $78,064.32 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,028 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · derivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,545 Underlying: Common Stock, par value $0.0001 · 16,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 7,313 | $9.88 | $72,252.44 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,454 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010778 · tm245213-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 7,889 | $2.69 | $21,221.41 |
DisclosureSEC source: 0001104659-24-009539 · tm244961-2_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,222 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009539 · tm244961-2_4seq1.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,325 Underlying: Common Stock, par value $0.0001 · 26,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 11,697 | $9.80 | $114,630.60 |
DisclosureSEC source: 0001104659-24-009539 · tm244961-2_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,333 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 26,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009539 · tm244961-2_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:30 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 168,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007860 · tm244341-2_4seq1.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,200 Underlying: Common Stock, par value $0.0001 · 168,200 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:30 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 470,000 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001104659-24-007860 · tm244341-2_4seq1.xml · derivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock, par value $0.0001 · 470,000 shares Expires 2034-01-25 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:54 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 126 | $2.81 | $354.06 |
DisclosureSEC source: 0001104659-23-086908 · tm2322669-5_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,255 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2023 through July 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2023. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:30 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011206 · tm235551-1_4seq1.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,850 Underlying: Common Stock, par value $0.0001 · 18,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:30 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 8,422 | $15.04 | $126,666.88 |
DisclosureSEC source: 0001104659-23-011206 · tm235551-1_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,129 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:30 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 18,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011206 · tm235551-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:09 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 16,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009973 · tm235311-2_4seq1.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,090 Underlying: Common Stock, par value $0.0001 · 16,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:09 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 7,658 | $13.78 | $105,527.24 |
DisclosureSEC source: 0001104659-23-009973 · tm235311-2_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,601 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:09 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009973 · tm235311-2_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:09 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,938 | $10.21 | $19,784.07 |
DisclosureSEC source: 0001104659-23-009973 · tm235311-2_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,713 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:33 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 107,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009355 · tm235142-4_4seq1.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,100 Underlying: Common Stock, par value $0.0001 · 107,100 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:33 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 302,900 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-23-009355 · tm235142-4_4seq1.xml · derivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,900 Underlying: Common Stock, par value $0.0001 · 302,900 shares Expires 2033-01-30 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $9.95 | $29,919.65 |
DisclosureSEC source: 0001104659-22-123652 · tm2231773-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,775 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| October 30, 2022 Filed Oct 31, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $12.77 | $38,399.39 |
DisclosureSEC source: 0001104659-22-112955 · tm2229283-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,782 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:08 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $12.77 | $38,412.16 |
DisclosureSEC source: 0001104659-22-105233 · tm2227318-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,789 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.